Feng et al. [29] indicated that, while bevacizumab targets VEGFA to inhibit tumor angiogenesis, ETV5-mediated CCL2 secretion acts as a parallel bypass to increase tumor angiogenesis to promote bevacizumab resistance. Here, VEGFA is linked to neoplasm.